Noninvasive biomarkers in NAFLD and NASH - current progress and future promise (Q57173225)

4

0 references

Leon A Adams

2

object named as

Leon A Adams

0 references

author name string

Victor de Lédinghen

3

0 references

Grace Lai-Hung Wong

4

0 references

Silvia Sookoian

5

0 references

Leon A. Adams

Nature Reviews Gastroenterology & Hepatology

2

0 references

language of work or name

English

0 references

publication date

August 2018

0 references

29 May 2018

0 references

published in

0 references

volume

15

0 references

issue

8

0 references

page(s)

461-478

0 references

cites work

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A 21-year experience with major hemorrhage after percutaneous liver biopsy

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Exceeding the limits of liver histology markers

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Fatty liver index and mortality: the Cremona study in the 15th year of follow-up

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The utility of radiological imaging in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1 H-MRS?

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Biomarkers of liver cell death

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

An apoptosis panel for nonalcoholic steatohepatitis diagnosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The plasma lipidomic signature of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Adipokines and cytokines in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Adipokines in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Serum Ferritin Is An Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Liver fibrosis scores predict liver disease mortality in the United States population.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Hyaluronic acid concentration in liver diseases.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: A meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Biomarkers of NAFLD progression: a lipidomics approach to an epidemic

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Plasma metabolomic profile in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021

PNPLA3gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038/S41575-018-0014-9

7 January 2021